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Abstract.  In most trials, at least 30–60% of patients with Graves’ disease treated with antithyroid drugs relapse within
2 years after therapy withdrawal.  At present, there are no prognostic parameters available early in treatment to indicate
patients likely to achieve long-term remission.  Because thyrotropin receptor autoantibodies (TRAb) are specific for
Graves’ disease, we evaluated the ability of their levels and of their rate of change to predict long-term prognosis.  In our
study 216 consecutive patients with newly diagnosed Graves’ disease started a therapy with methimazole.  Patients were
treated until they achieved euthyroidism and TRAb were measured at 6-month intervals throughout a follow up of
120 months.  Our study demonstrated that at the onset of hyperthyroidism patients’ age, sex, fT4 levels and goiter size had
no prognostic value in predicting long-term prognosis (respectively p = 0.79; p = 0.98; p = 0.83; p = 0.89).  On the
contrary, at the time of diagnosis TRAb titer was a good predictor of the final outcome (p<0.001); a titer equal to (or) more
than 46.5 UI/L could identify patients who had never achieved long-term remission with a sensitivity of 52% and a
specificity of 78%.  Also fall rate of TRAb at 6 months of follow up and after therapy withdrawal were useful to predict
the final outcome (p<0.001).  At 6 months of follow up the time of therapy withdrawal, a decrease of TRAb lower than
52.3% or even its increase could identify patients who had never achieved permanent remission with a sensitivity of 55%
and a specificity of 79.1%.  No single parameter among TRAb, satisfactory identified a sub-set of patients who achieved
long remission.  Accordingly to our data, the best result in predicting long term remission is probably given by the
presence of at least one of the two features evaluated at 6 months (TRAb titer and/or percentage of TRAb fall rate), with a
sensitivity of 63% and specificity of 88%.  TRAb titers evaluated both at the onset of hyperthyroidism that at 6 months of
therapy or their rate of fall at 6 months and at ATD withdrawal are predictors of outcome.  However, the presence of at
least one, between titers of TRAb or their rate of fall at six months, resulted to be the best predictor of remission with the
higher sensitivity and specificity.
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GRAVES’ disease (GD) is an autoimmune disorder,
characterized by the presence of circulating thyrotropin
receptor auto antibodies (TRAb) [1]; the thyroid-
stimulating activity of TRAb is responsible for the
development of hyperthyroidism.  Treatment strategies
for Graves’ hyperthyroidism include medical therapy
with antithyroid drugs (ATD), or thyroid ablation with
radioiodine or surgery [2].  Conservative therapy with
ATD is the first choice treatment in Europe [3] and
drug selection is largely determined by local practice,
methimazole being mostly used.  A long-term treat-
ment of about 12–18 months is usually adopted, which
requires careful monitoring of patients for side effects
such as allergic reactions, agranulocytosis and hepato-
toxicity [4, 5].  At therapy withdrawal, relapse rate is
very high (50–60%), and many patients need further
treatment [6, 7].  Therefore, some authors, particularly
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in the United States, favor thyroid ablation as the first
choice treatment in most instances [7].  On the other
hand, ablative treatment is not devoid of unwanted
side-effects.  Thyroid surgery entails perioperative
morbidity, postoperative hypothyroidism, and hospi-
talization costs [2]; radioiodine treatment, in turn, im-
plies subsequent hypothyroidism and the possibility of
secondary neoplasia [8].
Therefore, one major issue with GD is the identifica-
tion of patients likely to achieve long-term remission
after conservative therapy [7, 9–11].  Assessing prog-
nostic parameters may be useful to select those patients
who are unlikely to benefit from ATD and consequently
directly suitable for an ablative treatment which would
spare a long, useless and potentially harmful pharma-
cological therapy.
The role of TRAb levels, as a predictor of outcome
for ATD treatment, is rather controversial [10–14]:
many variables, such as prospective vs retrospective
studies, laboratory methods adopted to evaluate TRAb
(TBII vs TSab), time of TRAb measurement (basal vs
post-therapy values) and ATD treatment (type, dosage
and duration) give complicated the overall interpreta-
tion of this issue.
Ideally, TRAb levels would be a very useful clinical
tool if their measurement, at the time of diagnosis and/
or TRAb level changes during ATD treatment, could
discriminate with sufficient specificity and sensitivity,
those patients who benefit from a short-term ATD
course from those who require a more prolonged ATD
treatment or must be assigned to ablative treatment op-
tions.
To further explore this hypothesis, we designed a
prospective study aimed to investigate, the role of
TRAb titer, as well as other potential predictors, in
achieving long term remission after ATD treatment.
Materials and Methods
Patients
From January 1993 to January 1995, we evaluated
216 consecutive patients (31 males and 185 females)
with newly diagnosis of GD, at the outpatient clinics of
the Endocrinology Unit of the University of Brescia
and the Nuclear Medicine Unit of Spedali Civili of
Brescia.  The diagnosis of GD was based on commonly
accepted clinical and laboratory criteria: hyperthyroid-
ism, diffuse goitre without nodular formations at ultra-
sound, uniform pattern of uptake on scan with Tc-99m,
presence in serum of TRAb.  Hyperthyroidism was di-
agnosed on the basis of signs and symptoms of thyro-
toxicosis, even without infiltrative opthalmopathy, and
on the basis of raised free thyroxin (fT4) levels with
undetectable thyrotropin (TSH).  Thyroid volume was
assessed at diagnosis by ultrasound in all patients,
using the ellipsoid formula (normal values <18 mL in
males, <14 mL in females).
Study protocol
According to the study protocol, all patients started
therapy with a standard dose of methimazole (20 mg/
day).  A follow-up was planned up to 120 months, with
control visit every three months during the first year,
and every six months later on.  A careful medical ex-
amination and laboratory assessment of TRAb, TSH
and fT4 level were performed at any visit.  The same
examination was performed at therapy withdrawal.
Accordingly, pharmacological therapy was adjusted
to keep euthyroid status, when TSH was at or above
normal range levels and fT4 at or below serum level.
When a condition of “euthyroidism” was achieved,
patients were immediately treated with 2.5 mg of
methimazole for 3 further months.  After therapy with-
drawal, if a relapse occurred (clinical and biochemical
signs of hyperthyroidism), treatment with methimazole
at the same dosage (20 mg/day) was restarted.
Patients were eligible for ablative treatment (surgery
or radioactive iodine) if they a) showed adverse drug
reactions; b) relapsed at least three times after therapy
withdrawal; c) had relevant symptoms related to tra-
cheal compression; or d) did not achieve a condition
of euthyroidism after at least one year of consecutive
methimazole treatment (20 mg/day).
All the patients enrolled in this study completed the
120 month follow-up period, unless they were submit-
ted to ablative treatment.  At the end of the observation
period, patients were assigned to four categories, as
follows: Group 1 included those patients who achieved
long-term euthyroidism (at least 48 months) after ther-
apy withdrawal and had no relapse; Group 2 included
patients who achieved long-term euthyroidism after at
least one relapse; Group 3 consisted of patients submit-
ted to ablative treatment (surgery or radioactive iodine)
after at least three transitory remissions and subsequent
relapses; Group 4 included patients who underwent
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ablative treatment without any prior evidence of re-
mission.  Groups 1 and 2 were collectively included in
the “Remission” category (REM), whereas groups 3
and 4 were considered as an “Ablation” (ABL) cate-
gory.
The study was conducted according to the principles
of the Helsinki declaration and the guidelines of the
institutional ethical committee.  Written informed con-
sent was obtained from all subjects.
Methods
Serum free thyroxin (fT4) was determined by com-
mercially available radioimmunoassay (fT4 RIA CT-
RADIM, Rome, Italy; range: 8.0–18.0 pg/ml); serum
thyroid stimulating hormone (TSH) was measured by a
sensitive immunoradiometric assay (TSH IRMA Co
Tube 2nd generation; range: 0.2–4.0 mIUI/L-BIORAD,
Hercules, CA, USA).
TSH receptor antibodies (TRAb) were determined
by a commercial RRA (TRAK-Assay, B.R.A.H.M.S:
Diagnostica; normal range <9 UI/L).
Statistics
Differences among subgroups of patients, at baseline
or at different time-point during follow-up, were evalu-
ated by ANOVA.  Linear association between the pa-
rameters under examination was evaluated by Pearson
correlation analysis.  To evaluate the influence of fT4
and TRAb titer on prognosis, i.e. remission vs. thyroid
ablation, logistic regression analysis was used (with
age, thyroid size and sex as covariates).  The sensitivity
and the specificity of TRAb and fT4 cut-off were deter-
mined by the ROC-curve method [15].  Event-free sur-
vival (relapse/thyroid ablation after ATD treatment)
was documented using a Kaplan-Meier curve.  A p
value ≤0.05 was considered statistically significant.
Values are presented as mean ± standard deviation.
Data were analyzed with SPSS for Windows (realized
12.0).
Results
Of the 216 patients who completed the follow-up, 71
(32.9%) achieved long-term euthyroidism after ATD
withdrawal without relapse (Group 1); 20 (9.2%) pa-
tients achieved long-term euthyroidism after at least
one relapse (Group 2); 76 (35.2%) subjects underwent
ablative treatment (surgery or radioactive iodine) after
many transitory remissions and subsequent relapses
(Group 3); 49 (22.7%) patients never achieved remis-
sion on ATD treatment and underwent ablative treat-
ment (Group 4).  Accordingly, at the end of follow up,
91 patients (Group 1 and 2) achieved long-term remis-
sion (REM) and 125 patients (Group 3 and 4) under-
went ablative treatment (ABL).  Among ABL groups
two subjects were submitted to ablative treatment be-
cause showing symptoms of tracheal compression after
a mean period of 9 months of ATD.  All the others
patients were submitted to ablative treatment because
they didn’t achieve euthyroidism after at least one
years of therapy and/or relapsed at least three times
after therapy withdrawal.  No drug side effects were
observed in our study; consequently no patients were
submitted to ablative treatment for this reason.
Table 1 summarizes the clinical characteristics of
patients at entrance in the study, as a whole and in sep-
arate groups, according to the above definitions.
Table 1. Clinical characteristics of patients at the time of diagnosis






N° 71 20 76 49 91 125 216
Age (years) 39.9 ± 11.2 36.0 ± 11.4 37.6 ± 13.4 42.6 ± 14.9 37.9 ± 11.3 40.1 ± 13.9 39.4 ± 13.1
Sex: F (%) 85.9 85.0 84.2 87.8 85.7 85.6 85.6
fT4 (pg/ml) 42.6 ± 16.4 52.9 ± 18.6** 43.4 ± 20.3 48.5 ± 19.4 44.8 ± 17.4 45.4 ± 20.1 45.2 ± 18.9
TRAb (UI/L) 39.7 ± 40.3 51.7 ± 77.8§ 63.4 ± 84.5§ 124.1 ± 115.9§ 42.4 ± 50.6 87.2 ± 102.1* 68.4 ± 87.0
Size (<40 mL) 35% 35% 30% 34% 35% 32% 33.3%
Size (40–70 mL) 51% 50% 54% 53% 51% 54% 52.3%
Size (>70 mL) 14% 15% 16% 13% 14% 14% 14.4%
*p<0.001 REM vs ABL, **p<0.001 Group 1 vs Group 2, §p<0.001 Group 1 vs Group 2, Group 3 and Group 4
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At the time of diagnosis, no statistical difference was
observed among REM and ABL for age, sex, fT4 levels
and goiter size.  Indeed, basal TRAb titer was signifi-
cantly higher in ABL than in REM (87.2 ± 102.1 vs
42.4 ± 50.6 UI/L p<0.001).  At the onset of hyper-
thyroidism the age of patients were not correlated to
fT4 and TRAb levels (Pearson’s correlation = 0.19,
0.17 respectively).  At six months of follow up, all the
216 patients were still in treatment with antithyroid
drugs.  The whole duration of ATD therapy was sig-
nificantly shorter in REM (17.5 ± 6.9 months) than in
ABL patients (26.4 ± 11.1 months) (p<0.01).  On the
contrary, time lapsed from diagnosis to first withdraw-
al was sensible longer in patients who never relapsed
(Group 1) than in those had at least one (Group 2 and
Group 3) (Table 2) (p<0.001).  Moreover, among these
two groups, the subjects that at the end of follow-up
arisen in remission group (Group 2), had a longer peri-
od of time from therapy withdrawal to first relapse than
the Group 3 patients (p<0.05).  Total duration of thera-
py, time lapsed from diagnosis to first therapy with-
drawal and time lapsed from therapy withdrawal to
first relapse and the decrease of TRAb levels after
therapy withdrawal are reported in Table 2.
At the onset of hyperthyroidism mean fT4 level was
45.2 ± 18.9 pg/ml.  Interestingly, logistic regression
analysis showed that, among the selected variables
available at the time of diagnosis, the only statistically
significant predictor of the risk of first relapse after
therapy withdrawal was fT4 levels (Table 3).  More-
over, among REM patients initial fT4 levels were
significantly lower in those who had never relapsed
(Group 1) (p<0.001).
Predictors for remission or ablative treatment
Logistic regression analysis showed that, among the
selected variables available at the time of diagnosis, the
only statistically significant predictor of the following
ablative treatment was TRAb titer (Table 4).  Its prog-
nostic value was evaluated by the ROC analysis which
indicated a titer of 46.5 UI/L as the best cut off.  In fact,
an initial TRAb titer ≥46.5 UI/L identified patients who
had never achieved remission with a sensitivity of 52%
Table 2. Details of duration of therapy, time lapsed from diagnosis to first therapy withdrawal; time lapsed from therapy withdrawal
to first relapse and percentage of TRAb fall rate at the therapy withdrawal and at 6 months of follow-up
REM ABL
Group 1 Group 2 Group 3 Group 4
Time lapsed from diagnosis to first therapy withdrawal (months) 13.9 ± 7.1 7.8 ± 5.5* 8.2 ± 7.0* —
Time lapsed from therapy withdrawal to first relapse (months) — 14.4 ± 9.3 7.5 ± 6.4** —
Number of relapses (average, range) — 1.05 (1–2) 1.48 (1–3) —
Total duration of ATD therapy (months) 13.9 ± 7.1 19.6 ± 6.6° 21.2 ± 4.3° 28.2 ± 15.4§
TRAb rate of fall at 6 months of follow up (%) 42.8 48.1 29.9°° –11.1^
TRAb rate of fall at therapy withdrawal (%) 68.3 54.3^^ 38.7^^ —
*p<0.001 Group 1 vs Group 2 and vs Group 3, **p<0.05 Group 2 vs Group 3, °p<0.05 Group 1 vs Group 2 and vs Group 3, §p<0.001
Group 1 vs Group 4, °°p<0.01 Group 1 and Group 2 vs Group 3, ^p<0.001 Group 1 and Group 2 and Group 3 vs Group 4, ^^p<0.001
Group 1 vs Group 2 and Group 3
Table 3. Multivariate predictors of risk of first relapse after
therapy withdrawal
Predictors OR (95% CI) Wald statistics
Age 0.9 (0.7–1.3) NS
Gender (male) 0.8 (0.6–1.7) NS
Thyroid size 1.0 (0.8–1.2) NS
fT4 1.2 (0.9–1.5) P<0.001
TRAb levels 0.9 (0.6–1.1) NS
Abbreviations: OR, odds ratio; CI, confidence interval; NS, not
significant
Table 4. Multivariate predictors of following ablative treat-
ment
Predictors OR (95% CI) P Value
Age 1.0 (0.9–1.0) NS
Gender (male) 0.8 (0.4–1.8) NS
Thyroid size 0.8 (0.5–1.2) NS
fT4 0.9 (0.4–1.5) NS
TRAb levels 1.0 (1.1–1.3) <0.001
Abbreviations: OR, odds ratio; CI, confidence interval; NS, not
significant
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and a specificity of 78%.
TRAb titer at 3 and 6 months of ATD therapy and at
therapy withdrawal were also available in all patients;
only at 6 months of therapy and superimposable to
basal titer, it was a significantly associated to the risk
of thyroid ablation (p<0.001).  At this time, a TRAb
titer ≥30.7 UI/L identified patients who had never
achieved remission with sensitivity of 52% and speci-
ficity of 80%.  Moreover, also a percentage of TRAb
fall rate at 6 months of therapy and at therapy with-
drawal from the basal data were both significant pre-
dictors of a positive outcome (p<0.001) (Table 5).
TRAb at diagnosis and their fall rate percentage at
six months of therapy are reported in Table 6.
Results show that no single parameter among TRAb,
satisfactory identified a sub-set of patients who
achieved long remission.  Accordingly to our data, the
best result in predicting long term remission is prob-
ably given by the presence of at least one of the two
features evaluated at 6 months (TRAb titer and/or
percentage of TRAb fall rate), with a sensitivity of
63% and specificity of 88%.
Discussion
Conservative therapy with ATD is the first choice
treatment in Europe and it is proven to be effective in
achieving euthyroidism in Graves’ patients [3], even if
long-term remission after therapy withdrawal is unsat-
isfying with relapse rates of 30–50% [9, 16–20].  How-
ever, if the great rate of relapse(s) may be related to
TRAb levels and/or other parameters, such as gender,
age, fT4 levels or goiter size is still controversial [13,
14, 20–23].  As known, the prevalence of Graves’ pa-
tients is associated to gender, and, in accordance with
this view, our subjects were predominant female
(85.6% females, 24.4% males).  Nevertheless, differ-
ently with previous reports [24, 25], any correlation
between gender and relapse(s) was detected (p =
0.973).  In a subgroup of women affected by GD, and
after pregnancy, age resulted associated to relapse [26];
again, our data didn’t show any correlation between
age and this risk; probably it may due to different selec-
tion of patients.
High levels of fT4 at the onset of hyperthyroidism
were already investigated as potential predictor of re-
lapse(s) with discordant results [27–29].  In agreement
with Weetman et al. [28], also our data showed that
high levels of fT4 are significant associated to the risk
of relapse(s) (p<0.001).
Clague et al. suggested a correlation between TRAb
titers and fT4 levels at the time of diagnosis [30].  Our
data didn’t confirm this hypothesis; we believe, as al-
ready suggested by others [31, 32], that in spite of
TRAb fundamental role in the etiopathogenesis of GD,
many other biochemical signals produced by the im-
munological cells can modulate the synthesis and the
excretion of thyroid hormone.
The distribution of goiter size among the Groups, at
time of recruitment, was homogeneous.  Recently, it
has been suggested that goiter size could be a predictor
of relapse(s) in GD [33, 34]: bigger is the volume,
higher is the risk [33, 34], but any correlation between
goiter size and relapse(s) rate of the disease was present
in this study.
The major problem of GD, and the mainly end-point













Initial TRAb 46.5 52 78.0 52.0 76.9
TRAb at 6 M of follow up 30.7 52 80.0 53.2 78.7
Change in TRAb at 6 M of follow-up 52.3 55 79.1 55.0 73.0
Change in TRAb at therapy withdrawal 55.8 57 83.3 56.1 79.2
PPV = Positive predictive value; NPV = Negative predictive value.
Table 6. TRAb titer at the onset of hyperthyroidism and their













>46.5 >52.3 9 (9.9%) 24 (19.2%)
<46.5 <52.3 71 (77.2%) 60 (48%)
>46.5 <52.3 11 (12.1%) 41 (32.8%)
<46.5 >52.3 — —
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of this resource, is the difficulty to find factors able to
predict which patients are likely to achieve long-term
remission after conservative medical therapy [7, 10,
13, 35].
Previous studies demonstrated an inverse correlation
between patients’ age and fT4 serum levels at the onset
of hyperthyroidism [24, 25], patients’ age and titer of
TRAb at the time of diagnosis [24], patients’ age and
relapse risk after therapy withdrawal [36], suggesting
that the autoimmune thyroid process was more prone
to subside in patients older than 40 years.  Our study
didn’t confirm this hypothesis: age distribution among
Groups was casual and not correlated to fT4 levels, to
TRAb titers and to the final outcome.  We concluded
that patients’ age at the time of diagnosis couldn’t pre-
dict the final outcome, but the mean age in our study
was less than in previous studies (39.3 ± 13.0 years).  It
could be a consequence of an earlier diagnosis, pro-
bably due to our particularly attention to thyrotoxicosis
as previously demonstrated [37, 38].
At the onset of hyperthyroidism no different fT4 lev-
els were present among REM and ABL patients.  Our
study confirmed previous data [39, 40] obtained in
adults and in children of the absence of influence of
fT4 on the outcome.
As TRAb are considered the hall markers of GD [41,
42], their persistence in the blood of patients treated
with ATD may indicate on going active disease.  For
this reason many investigators are focused on the pos-
sible role played by TRAb as predictors of GD out-
come [10–13, 20, 43, 44].
In the onset of hyperthyroidism, TRAb levels result-
ed significant lower in Group1 than the others
(p<0.001); moreover, their prognostic feature was con-
firmed during follow-up, which is already the longer
never described (120 months).  TRAb titer at diagnosis
was strongly associated with the final outcome (sensi-
tivity 52%, specificity 78%, p<0.001), in agreement
with other authors [10–13].
With the aim to improve this results, we have evalu-
ated the title of TRAb at 3 and 6 months of therapy, at
therapy withdrawal, and also the percentage of their
fall rate during ATD (at 6 months) and at its end.  As
already reported by Vitti et al. [9] only titer of TRAb at
6 months of ATD was associated to the outcome (sen-
sitivity 52%, specificity 80%, p<0.001).  Also a per-
centage of fall TRAb rate more than 50% at 6 months
of therapy and at ATD withdrawal were eligible as
predictors of outcome (sensitivity 55% and 57%; spec-
ificity 79.1% and 83.3%, respectively).  No single pa-
rameter among TRAb, satisfactory identified a sub-set
of patients who achieved long remission.  Accordingly
to our data, the best result in predicting long term
remission is probably given by the presence of at least
one of the two features evaluated at 6 months (TRAb
titer and/or percentage of TRAb fall rate), with a sen-
sitivity of 63% and specificity of 88%.
Finally, we have also evaluated if was present signif-
icant differences between total time of therapy and
time lapsed from diagnosis to achieve euthyroidism
among Groups.
The ABL subjects presented a longer whole duration
of ATD than REM patients (p<0.01): obviously, this
result is due to the fact that subjects with more relapses
re-started therapy more times.  Among patients that at
the end of follow-up obtained completely remission,
anti-thyroid drug therapy was shorter in patients with-
out any relapse (Group 1) than the others (Group 2 and
Group 3) (p<0.05); obviously, also this data is in line
with the above explanation.  On the contrary and quite
surprisingly, time lapsed from diagnosis to first with-
drawal (time to achieve euthyroidism) was signifi-
cantly longer in Group 1 than Group 2 and Group3
(p<0.001).
We supposed that patients who achieved permanent
remission without any relapse (Group 1) were affected
by a “resistance” form of GD, which required a long-
time therapy to achieve euthyroidism.  According to
our data and with previous investigations on the role of
ATD on the responsive effects of thyroid tissue by
TRAb modulation [20], it could be hypothesized that in
patients with a “resistance” Graves’ disease, it is more
difficult to obtain euthyroidism; on the other end, if
euthyroidism is achieve, there are more possibility to
remain euthyroid.  In fact, our data clearly showed
that a longer-time treatment (more than 12 months)
to achieve euthyroidism was associated with major
decrease of TRAb, and also with better prognosis.
Moreover, supposing early relapses associated with
a “greater” aggressiveness of GD, and subsequently
with a worst prognosis, we have evaluated time lapsed
from therapy withdrawal to first relapse (Table 2).  Ac-
cording with our hypothesis, it resulted correlated with
prognosis (p<0.05).
In conclusion, our data showed that at the time of di-
agnosis patients’ age, gender, fT4 and size goiter are
not associated to the final outcome.
TRAb titers evaluated both at the onset of hyperthy-
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roidism that at 6 months of therapy or their rate of fall
at 6 months and at ATD withdrawal are predictors of
outcome.  However, the presence of at least one, be-
tween titers of TRAb or their rate of fall at six months,
resulted to be the best predictor of remission with the
higher sensitivity and specificity.
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